<DOC>
	<DOC>NCT00697775</DOC>
	<brief_summary>In this study the safety and immunogenicity of 2 different formulations of the candidate HBV-MPL vaccine administered according to a 0, 6-month schedule were explored and compared to that of Engerix™-B in healthy adolescents aged 11 to 15</brief_summary>
	<brief_title>Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents</brief_title>
	<detailed_description>At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age: between 11 and 15 years at the time of the first vaccination. Free of obvious health problems as established by medical history and clinical examination before entering into the study. Written informed consent obtained from the parents or guardians of the subject and from the subject himself/herself in all subjects 15 years of age. If the subject is female, she must be of nonchildbearing potential, if of childbearing potential, she must be abstinent or have used an adequate contraceptive for one month prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series Use of any investigational or nonregistered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine. Administration of chronic (defined as more than 14 days) immunosuppressants or other immunemodifying drugs within six months of vaccination. Planned administration of a vaccine not foreseen by the study protocol during the period starting from one week before each dose of vaccine and ending 30 days after. Previous vaccination against hepatitis B virus. Previous vaccination with vaccine containing MPL. Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Acute disease at the time of enrollment. Hepatomegaly, right upper quadrant abdominal pain or tenderness. Axillary temperature of ≥ 37.5° C. Administration of immunoglobulin and / or any blood product within the six months preceding the first dose of study vaccine or planned administration during the study period. Pregnant or lactating female. History of chronic disease deemed by the investigator to be relevant. Positive for antiHBV antibodies at screening</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Recombinant hepatitis B vaccine</keyword>
	<keyword>Adjuvant</keyword>
</DOC>